Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics

Future Medicinal Chemistry

Volumn 6, Issue 15, 2014, Pages 1645-1658

  Kuyucak, Serdar ^a   Norton, Raymond S ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HSTX1 TOXIN; ION TRANSPORT AFFECTING AGENT; PEPTIDE DERIVATIVE; PEPTIDE TOXIN DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL TOXIN; SHK TOXIN; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL TOXIN; UNCLASSIFIED DRUG; COELENTERATE VENOM; PEPTIDE; SCORPION VENOM; SHK NEUROTOXIN; TX1 TOXIN, HETEROMETRUS SPINNIFER; VOLTAGE GATED POTASSIUM CHANNEL;

AUTOIMMUNE DISEASE; BINDING AFFINITY; CRYSTAL STRUCTURE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PREDICTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; THERMODYNAMICS; ANIMAL; AUTOIMMUNE DISEASES; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; CNIDARIAN VENOMS; DRUG DESIGN; HUMANS; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; SCORPION VENOMS; THERMODYNAMICS;

EID: 84911861938     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/FMC.14.98     Document Type: Review

References (98)

1. Ashcroft FM. Ion Channels and Disease: Channelopathies. Academic Press, CA, USA (2000).
2. + channel modulators for the treatment of neurological disorders and autoimmune dieseases. Chem. Rev. 108, 1744-1773 (2008).
3. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Disc. 8, 982-1001 (2009).
4. Saez NJ, Senff S, Jensen JE et al. Spider-venom peptides as therapeutics. Toxins 2, 2851-2871 (2010).
5. Knapp O, McArthur JR, Adams DJ. Conotoxins targeting neuronal voltage-gated sodium channel subtypes: potential analgesics. Toxins 4, 1236-1260 (2012).
6. Chi V, Pennington MW, Norton RS et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 59, 529-546 (2012).
7. Beeton C, Wulff H, Standifer NE et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103, 17414-17419 (2006).
8. Beeton C, Pennington M, Wulf H et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67, 1369-1381 (2005).
9. Pennington MW, Beeton C, Galea CA et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol. Pharmacol. 75, 762-773 (2009).
10. Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 26, 531-568 (2006).
11. Gordon D, Chen R, Chung SH. Computational methods of studying the binding of toxins from venomous animals to biological ion channels. Physiol. Rev. 93, 767-802 (2013).
12. Rashid MH, Mahdavi S, Kuyucak S. Computational studies of marine toxins targeting ion channels. Mar. Drugs 11, 848-869 (2013).
13. Gilson MK, Zhou HX. Calculation of protein-ligand binding energies. Ann. Rev. Biophys. Biomol. Struct. 36, 21-42 (2007).
14. Deng Y, Roux B. Computations of standard binding free energies with molecular dynamics simulations. J. Phys. Chem. B 113, 2234-2246 (2009).
15. Christ CD, Mark AE, van Gunsteren WF. Basic ingredients of free energy calculations. J. Comput. Chem. 31, 1569-1582 (2010).
16. Steinbrecher T, Labahn A. Towards accurate free energy calculations in ligand-protein binding studies. Curr. Med. Chem. 17, 767-785 (2010).
17. Osborne R. Fresh from the biotech pipeline-2012. Nat. Biotechnol. 31, 100-103 (2013).
18. Norton RS, Pennington MW, Beeton C. Transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases.. In: In Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics. King GF (Ed.). Royal Society of Chemistry, London, UK (2014)(In press).
19. +channel in a lipid membrane-like environment. Nature 450, 376-382 (2007).
20. Payandeh J, Scheuer T, Zheng N, Catterall WA. The crystal structure of a voltage-gated sodium channel. Nature 475, 353-358 (2011).
21. Payandeh J, Scheuer T, Zheng N, Catterall WA. Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. Nature 486, 135-139 (2012).
22. Zhang X, Ren W, DeCaen P et al. Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature 486, 130-134 (2012).
23. Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 47, 409-443 (2002).
24. Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Ann. Rev. Biophys. Biomol. Struct. 32, 335-373 (2003).
25. Morris GM, Goodsell, DS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 19, 1639-1662 (1998).
26. Mintseris J, Pierce B, Wiehe K et al. Integrating statistical pair potentials into protein complex prediction. Proteins 69, 511-520 (2007).
27. Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein - protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125, 1731-1737 (2003).
28. De Vries SJ, van Dijk AD, Krzeminski M et al. HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 69, 726-733 (2007).
29. Warren GL, Andrews CW, Capelli, AM et al. A critical assessment of docking programs and scoring functions J. Med. Chem. 49, 5912-5931 (2006).
30. Patra SM, Bastug T, Kuyucak S. Binding of organic cations to gramicidin: a channel studied with AutoDock and molecular dynamics simulations. J. Phys. Chem. B111, 11303-11311 (2007).
31. Ander M, Luzhkov VB, Aqvist J. Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state - Docking and computer simulations of a homology model. Biophys. J. 94, 820-831 (2007).
32. Yi, H, Qiu, S, Cao, Z.J, Wu, Y.L, Li, W.X. Molecular basis of inhibitory peptide maurotoxin recognizing Kv1.2 channel explored by ZDOCK and molecular dynamic simulations. Proteins 70, 844-854 (2008).
33. Chen PC, Kuyucak S. Mechanism and energetics of charybdotoxin unbinding from a potassium channel from molecular dynamics simulations. Biophys. J. 96, 2577-2588 (2009).
34. Yu LP, Sun CH, Song DY et al. Nuclear magnetic resonance structural studies of a potassium channel - charybdotoxin complex. Biochemistry 44, 15834-15841 (2005).
35. Chen PC, Kuyucak S. Developing a comparative docking protocol for the prediction of peptide selectivity profiles: investigation of potassium channel toxins. Toxins 4, 110-138 (2012).
36. Humphrey W, Dalke A, Schulten K. VMD - visual molecular dynamics. J. Mol. Graph. 14, 33-38 (1996).
37. Bastug T, Kuyucak S. Importance of the peptide backbone description in modeling the selectivity filter in potassium channels. Biophys. J. 96, 4006-4012 (2009).
38. Phillips JC, Braun R, Wang W et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802 (2005).
39. Brooks BR, Brooks CL, MacKerell AD et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545-1614 (2009).
40. Frenkel D, Smit B. Understanding Molecular Simulation: From Algorithms to Applications. Academic Press, CA, USA (1996).
41. Leach AR. Molecular Modelling, Principles, Applications. Prentice Hall, NY, USA (2001).
42. Stansfeld PJ, Sansom MSP. Molecular simulation approaches to membrane proteins. Structure 19, 1562-1572 (2011).
43. Dror RO, Dirks RM, Grossman JP et al. Biomolecular simulations: a computational microscope for molecular biology. Annu. Rev. Biophys. 41, 429-452 (2012).
44. Bastug T, Kuyucak S. Molecular dynamics simulations of membrane proteins. Biophys. Rev. 4, 271-282 (2012).
45. Kollman PA, Massova I, Reyes C et al. Calculating structures and free energies of complex molecules: combining molecular mechanic and continuum models. Acc. Chem. Res. 33, 889-897 (2000).
46. Enyedy IJ, Egan WJ. Can we use docking and scoring for hit-to-lead optimization? J. Comput. Aided Mol. Des. 22, 161-168 (2008).
47. Schneider G. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9, 273-276 (2010).
48. Brown SP, Muchmore SW. Large scale application of high-throughput molecular mechanics with Poisson-Boltzmann surface area for routine physics-based scoring of proteinligand complexes. J. Med. Chem. 52, 3159-3165 (2009).
49. Singh N, Warshel A. Absolute binding free energy calculations: on the accuracy of computational scoring of protein-ligand interactions. Proteins 78, 1705-17123 (2010).
50. Michel J, Essex JW. Prediction of protein-ligand affinity by free energy simulations: assumptions, pitfalls and expectations. J. Comput. Aided Mol. Des. 24, 639-658 (2010).
51. Chodera JD, Mobley DL, Shirts MR et al. Alchemical free energy methods for drug discovery: progress and challenges. Curr. Opin. Struct. Biol. 21, 150-160 (2011).
52. deRuiter A, Oostenbrink C. Free energy calculations of protein - ligand interactions. Curr. Opin. Chem. Biol. 15, 547-552 (2011).
53. Mobley DL, Klimov PV. Perspective: alchemical free energy calculations in drug discovery. J. Chem. Phys. 137, 230901 (2012).
54. Kumar S, Bouzida SD, Swensen RH et al. The weighted histogram analysis method for free-energy calculations on biomolecules. J. Comput. Chem. 13, 1011-1021 (1992).
55. Chen PC, Kuyucak S. Accurate determination of the binding free energy for KcsA-charybdotoxin complex from the potential of mean force calculations. Biophys. J. 100, 2466-2474 (2011).
56. Park S, Schulten K. Calculating potentials of mean force from steered molecular dynamics simulations. J. Chem. Phys. 120, 5946-5961 (2004).
57. Bastug T, Chen PC, Patra SM, Kuyucak S. Potential of mean force calculations of ligand binding to ion channels from Jarzynski's equality and umbrella sampling. J. Chem. Phys. 128, 104-112 (2008).
58. Heinzelmann G, Bastug T, Kuyucak S. Free energy simulations of ligand binding to the aspartate transporter GltPh. Biophys. J. 101, 2380-2388 (2011).
59. Heinzelmann G, Bastug T, Kuyucak S. Mechanism and energetics of ligand release in the aspartate transporter GltPh. J. Phys. Chem B 117, 5486-5496 (2013).
60. Heinzelmann G, Chen PC, Kuyucak S. Computation of standard binding free energies of polar and charged ligands to the glutamate receptor GluA2. J. Phys. Chem B 118, 1813-1824 (2014).
61. Rashid MH, Heinzelmann G, Huq R et al. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. PLoS One 8, e78712 (2013).
62. + conduction and selectivity. Science 280, 69-77 (1998).
63. Rashid MH, Kuyucak S. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations. J. Phys. Chem. B 116, 4812-4822 (2012).
64. Khabiri M, Nikouee A, Cwiklik L et al. Charybdotoxin unbinding from the mKv1.3 potassium channel: a combined computational and experimental study. J. Phys. Chem. B 115, 11490-11500 (2011).
65. Chen R, Robinson, A, Gordon D, Chung SH. Modeling the binding of three toxins to the voltage-gated potassium channel (Kv1.3). Biophys. J. 101, 2652-2660 (2011).
66. Tudor JE, Pallaghy PK, Pennington MW, Norton RS. Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat. Struct. Biol. 3, 317-320 (1996).
67. Rauer H, Pennington M, Cahalan M, Chandy KG. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem. 274, 21885-21892 (1999).
68. Pennington MW, Rashid MH, Tajhya RB et al. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. FEBS Lett. 586, 3996-4001 (2012).
69. Regaya L, Beeton C, Ferrat G et al. Evidence for domain specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. J. Biol. Chem. 279, 55690-55696 (2004).
70. Savarin P, Romi-Lebrun R, Zinn-Justin S et al. Structural and functional consequences of the presence of a forth disulfide bridge in the scorpion short toxins: solution structure of the potassium channel inhibitor HsTx1. Protein Sci. 8, 2672-2685 (1999).
71. Rashid MH, Kuyucak S. Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3/Kv1.1 selectivity. J. Phys. Chem. B 118, 707-716 (2014).
72. Rashid MH, Huq R, Tanner M et al. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci. Rep. 4, 4509 (2014).
73. Billen B, Bosmans F, Tytgat J. Animal peptides targeting voltage-activated sodium channels. Curr. Pharm. Des. 14, 2492-2502 (2008).
74. Clare JC. Targeting voltage-gated sodium channels for pain therapy. Expert Opin. Investig. Drugs 19, 45-62 (2010).
75. Twede VD, Miljanich G, Olivera BM, Bulaj G. Neuroprotective and cardioprotectiveconopeptides: an emerging class of drug leads. Curr. Opin. Drug Discov. Devel. 12, 231-239 (2009).
76. Norton RS. μ-conotoxins as leads in the development of new analgesics. Molecules 15, 2825-2844 (2010).
77. Cruz LJ, Gray WR, Olivera BM et al. Conusgeographus toxins that discriminate between neuronal and muscle sodium channels. J. Biol. Chem. 260, 9280-9288 (1985).
78. Li RA, Ennis, IL, French RJ et al. Clockwise domain arrangement of the sodium channel revealed by μ-conotoxin (GIIIA) docking orientation. J. Biol. Chem. 276, 11072-11077 (2001).
79. Hui K, Lipkind G, Fozzard HA, French RJ. Electrostatic and steric contributions to block of the skeletal muscle sodium channel by μ-conotoxin. J. Gen. Physiol. 119, 45-54 (2002).
80. +channel domain I P-loop: implications for toxin-pore binding geometry. Biophys. J. 85, 2299-2310 (2003).
81. + channel NaV1.4. PLoS One 9, e93267 (2014).
82. McArthur JR, Ostroumov V, Al-Sabi A et al. Multiple, distributed interactions of μ-conotoxin PIIIA associated with broad targeting among voltage-gated sodium channels. Biochemistry 50, 116-124 (2011).
83. McArthur JR, Singh G, O'Mara ML et al. Orientation of μ-conotoxin PIIIA in a sodium channel vestibule, based on voltage dependence of its binding. Mol. Pharmacol. 80, 219-227 (2011).
84. Tikhonov DB, Zhorov BS. Architecture and pore block of eukaryotic voltage-gated sodium channels in view of NaVAb bacterial sodium channel structure. Mol. Pharmacol. 82, 97-104 (2012).
85. Chen R, Chung SH. Mechanism of tetrodotoxin block and resistance in sodium channels. Biochem. Biophys. Res. Commun. 446, 370-374 (2014).
86. +channel localized by mutant cycle analysis. Biochemistry 37, 4407-4419 (1998).
87. Wilson MJ, Yoshikami D, Azam L et al. μ-conotoxins that differentially block sodium channels NaV1.1 through NaV1.8 identify those responsible for action potentials in sciatic nerve. Proc. Natl. Acad. Sci. USA 108, 10302-10307 (2011).
88. Catterall WA. Ion channel voltage sensors: structure, function, and pathophysiology. Neuron 67, 915-928 (2010).
89. Middleton RE, Warren VA, Kraus RL et al. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry 41, 14734-14747 (2002).
90. Schmalhofer WA, Calhoun J, Burrows R et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 74, 1476-1784 (2008).
91. Xiao, Y et al. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain II voltage sensor in the closed configuration. J. Biol. Chem. 283, 27300-27313 (2008).
92. Sokolov S, Kraus RL, Scheuer T, Catterall WA. Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II. Mol. Pharmacol. 73, 1020-1028 (2008).
93. Xiao Y, Blumenthal K, Jackson JO et al. The tarantula toxins ProTx-II and Huwentoxin-IV differentially interact with human NaV1.7 voltage sensors to inhibit channel activation and inactivation. Mol. Pharmacol. 78, 1124-1134 (2010).
94. + channel voltage sensors in domains II and IV. J. Biol. Chem. 286, 27301-27310 (2011).
95. Chen R, Chung SH. Conserved functional surface of anti-mammalian scorpion β-toxins. J. Phys. Chem. B 116, 4796-4800 (2012).
96. Chen R, Chung SH. Binding modes and functional surface of anti-mammalian scorpion α-toxins to sodium channels. Biochemistry 51, 77775-77782 (2012).
97. Muddana HS, Fenley AT, Mobley DL, Gilson MK. The SAMPL4 host-guest blind prediction challenge: an overview. J. Comput. Aided Mol. Des. 28, 305-317 (2014).
98. + channel: a computational approach based on experimental distance restraints extracted from thermodynamic mutant cycles. Biophys. J. 83, 2595-2609 (2002).